Restricted Indication for Maintenance Niraparib Therapy in Recurrent Ovarian Cancer Further Supported by Final Survival Analysis of NOVA Trial

Ursula A. Matulonis highlights previous data from the phase 3 ENGOT-OV16/NOVA trial initial readout and subsequent preplanned overall survival analysis, discusses new findings from the final analysis, and emphasizes how these data clarify some of the study’s limitations and reinforce the importance of adhering to the adjusted FDA label for niraparib in recurrent ovarian cancer.

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Boston ,Tampa ,Florida ,Ursulaa Matulonis , ,Boehringer Ingelheim ,Novartis ,Glaxosmithkline ,Division Of Gynecologic Oncology ,Harvard Medical School ,Astrazeneca ,Alkermes ,Society Of Gynecologic Oncology ,Gynecologic Oncology ,Annual Meeting ,Brock Wilson Family Chair ,New England Journal ,Blueprint Medicines ,Ovarian Cancer ,News ,